CASI Pharmaceuticals Inc (NASDAQ: CASI) stock closed at $6.13 on 12/15/23 after a major decline of -10.5%. Moreover, unusually high trading volume at 199% of normal accompanied the decline. The stock has declined -18.3% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CASI is expected to continue to be a modest Value Eraser.
CASI Pharmaceuticals has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. CASI Pharmaceuticals has a very low Appreciation Score of 12 but a very high Power Rating of 93, leading to the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment